Gate Bioscience is pioneering "molecular gates," proprietary small molecules designed to remove disease-causing proteins before they can exert harmful effects. The company’s discovery platform combines a library of gate compounds, secretion-focused assays, and expertise in secretory-pathway biology to rapidly generate selective candidates for inflammatory and neurological disorders. Led by Co-Founder and CEO Jordi Mata-Fink, Ph.D., Gate is currently advancing its lead molecular gate programs toward first-in-human clinical studies. Beyond these lead assets, the firm plans to broaden its pipeline across additional inflammatory and other therapeutic areas. Since inception, Gate Bioscience has raised a total of $135 million in venture funding, providing a significant capital base for R&D and early clinical work. The fresh Series B funds will specifically support clinical entry of lead programs and further platform expansion.

Total raised

$125M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2025